Vera Therapeutics, Inc. (VERA): Long-Term Debt
$74.84M
As of 2025-12-31
$75.23M
As of 2026-06-30
+44.5%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $74.84M | +47.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $50.69M | +1.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $49.88M | +101.0% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $24.81M | +404.0% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $4.92M | n/a | 2023-03-28, Balance as of period end |
| 2020-12-31 | $0 | n/a | 2022-03-28, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $74.84M | +47.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $9.70M | +1.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $291.77M | -1.4% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $29.16M | +3.0% |
| uniQure N.V. (QURE) | 2025-12-31 | $71.92M | +8.9% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $47.21M | n/a |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $2.01B | n/a |
Compare VERA, KURA, ARVN, MRVI side by side · Screen every company in Pharmaceutical Preparations ↗